Sartorius Stedim, FR0013154002

RBC kept Outperform on Sartorius Stedim stock at EUR 210 target

Published on 10/09/2026 at 11:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue was EUR 1.527 billion. Sartorius Stedim stock costs EUR 212.10 on October 9, 2026, 5.73 percent below its EUR 225.00 high.

Key points in brief

  • RBC kept an Outperform rating and a EUR 210.00 price target on October 6, 2026.
  • Sartorius Stedim reported EUR 1.527 billion in first-half 2026 revenue and EUR 463.7 million in EBITDA.
  • Lang & Schwarz showed EUR 212.10 on October 9, 2026, up 1.53 percent from the prior close.
  • The stock remained 5.73 percent below its EUR 225.00 52-week high.
Flatlay mit Laborpipetten, Filtermembranen, Schutzhandschuhen und ISIN-Karte FR0013154002
Sartorius Stedim Biotech Flatlay mit Laborpipetten, Filtermembranen, Aktien-Zertifikat und ISIN-Karte, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim (ISIN FR0013154002) was trading at EUR 212.10 at Lang & Schwarz on October 9, 2026 at 11:41 a.m. CEST, up 1.53 percent versus the prior close of EUR 208.90 on October 8, 2026. RBC had kept an Outperform rating and a EUR 210.00 price target on October 6, 2026, according to FinanzNachrichten.

Three dates frame the recovery

On July 22, 2026, Sartorius Stedim reported first-half revenue of EUR 1.527 billion, EBITDA of EUR 463.7 million and an EBITDA margin of 31.40 percent, according to Ideal Investor. On October 1, 2026, Goldman Sachs raised its price target from EUR 208.00 to EUR 223.00 and kept a Buy rating, as reported by FinanzNachrichten. On October 6, 2026, RBC retained its EUR 210.00 target and Outperform rating after updating its model for refunded US tariffs, the Mattek acquisition and currency effects, according to FinanzNachrichten.

At EUR 212.10 on October 9, 2026, the stock stood 5.73 percent below its EUR 225.00 52-week high. The market capitalization was EUR 20.6 billion on the same date, giving the analyst targets a valuation context without replacing the company figures.

What does the guidance mean for valuation?

The first-half report kept full-year revenue guidance at EUR 3.1538 billion and EBITDA guidance at EUR 989.2 million, according to Ideal Investor. Against first-half revenue of EUR 1.527 billion and EBITDA of EUR 463.7 million, the guidance gives investors a concrete benchmark for the second half of fiscal year 2026.

Stock remains below EUR 225.00 high

Lang & Schwarz showed Sartorius Stedim at EUR 212.10 in trading on October 9, 2026 at 11:41 a.m. CEST, plus 1.53 percent versus the EUR 208.90 prior close dated October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.

Sartorius Stedim Biotech market facts

  • Company: Sartorius Stedim Biotech S.A.
  • ISIN: FR0013154002
  • WKN: A2AJKS
  • Ticker: DIM.PA
  • Primary exchange: Euronext Paris
  • Price Lang & Schwarz (as of October 9, 2026, 11:41 a.m. CEST): EUR 212.10
  • Change versus prior close: plus 1.53 percent
  • Prior close Lang & Schwarz (October 8, 2026): EUR 208.90
  • Market capitalization: EUR 20.6 billion (as of October 9, 2026)
  • 52-week range: EUR 150.00-EUR 225.00 (as of October 9, 2026)
  • Sector / Industry: Health Care / Bioprocessing equipment
  • Index membership: CAC Next 20

Market context: Market report CAC 40.

More news and analyses on Sartorius Stedim stock

Disclaimer...

en | FR0013154002 | SARTORIUS STEDIM | boerse | 70275732 | bgmi